We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.27B
AUM Growth
+$432M
Cap. Flow
+$259M
Cap. Flow %
7.92%
Top 10 Hldgs %
37.03%
Holding
113
New
28
Increased
27
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$111M
2
MYGN icon
Myriad Genetics
MYGN
+$77.2M
3
BAX icon
Baxter International
BAX
+$36.4M
4
BFLY icon
Butterfly Network
BFLY
+$36.2M
5
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$35.7M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$52.7M
2
IRTC icon
iRhythm Holdings
IRTC
+$40.6M
3
PEN icon
Penumbra
PEN
+$32.4M
4
BMY icon
Bristol-Myers Squibb
BMY
+$28M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.98%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
76
CALL
DELISTED
Dynavax Technologies
DVAX
$4.92M 0.15%
+500,000
New +$4.12M
BLSA
77
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.91M 0.15%
464,103
-35,897
-7% -$405K
JYAC
78
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.57M 0.14%
464,103
-35,897
-7% -$371K
LAB icon
79
Standard BioTools
LAB
$313M
$4.43M 0.14%
980,505
-75,838
-7% -$417K
OSH
80
DELISTED
Oak Street Health, Inc.
OSH
$3.65M 0.11%
67,250
-5,201
-7% -$289K
ALNA
81
DELISTED
Allena Pharmaceuticals
ALNA
$395K 0.01%
284,285
– –
ACAD icon
82
CALL
Acadia Pharmaceuticals
ACAD
$4.9B
– –
-270,000
Closed -$14.4M
AMWL icon
83
American Well
AMWL
$220M
– –
-6,500
Closed -$3.29M
ARKG icon
84
PUT
ARK Genomic Revolution ETF
ARKG
$1.63B
– –
-900,000
Closed -$83.9M
BIIB icon
85
CALL
Biogen
BIIB
$30.5B
– –
-160,000
Closed -$39.2M
BMRN icon
86
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-371,700
Closed -$32.6M
BMRN icon
87
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-314,499
Closed -$27.6M
BMY icon
88
Bristol-Myers Squibb
BMY
$131B
– –
-451,275
Closed -$28M
CRSP icon
89
PUT
CRISPR Therapeutics
CRSP
$4.99B
– –
-41,000
Closed -$6.28M
EDIT icon
90
Editas Medicine
EDIT
$445M
– –
-29,900
Closed -$2.1M
ELV icon
91
Elevance Health
ELV
$84.9B
– –
-164,238
Closed -$52.7M
HSIC icon
92
Henry Schein
HSIC
$9.83B
– –
-395,161
Closed -$26.4M
IONS icon
93
Ionis Pharmaceuticals
IONS
$9.06B
– –
-263,412
Closed -$14.9M
IOVA icon
94
PUT
Iovance Biotherapeutics
IOVA
$2.77B
– –
-500,000
Closed -$23.2M
IRTC icon
95
iRhythm Holdings
IRTC
$4.21B
– –
-171,028
Closed -$40.6M
LH icon
96
Labcorp
LH
$25.6B
– –
-149,108
Closed -$26.1M
MRNA icon
97
PUT
Moderna
MRNA
$21.5B
– –
-540,000
Closed -$56.4M
PACB icon
98
PUT
Pacific Biosciences
PACB
$363M
– –
-320,000
Closed -$8.3M
PFE icon
99
Pfizer
PFE
$149B
– –
-685,125
Closed -$25.2M
RCUS icon
100
CALL
Arcus Biosciences
RCUS
$3.56B
– –
-237,300
Closed -$6.16M
1 2 3
4
5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
PWA
Pitcairn Wealth Advisors Conshohocken, Pennsylvania $1.09B AUM

PFM Health Sciences's Q1 2021 Portfolio in Review

As of Q1 2021, PFM Health Sciences held 113 positions worth $3.27B, up 15% from $2.84B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

PFM Health Sciences deployed $259M of net new capital in Q1 2021, opening 28 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,055,510 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Penumbra, an estimated $32.4M trimmed.

  • PFM Health Sciences's largest Q1 2021 buy was Neurocrine Biosciences: 1,055,510 shares worth $103M.
  • PFM Health Sciences added most to Eli Lilly in Q1 2021, an estimated $34.2M increase.
  • PFM Health Sciences's biggest Q1 2021 reduction was Penumbra, cutting an estimated $32.4M.
  • PFM Health Sciences fully exited Elevance Health in Q1 2021, selling an estimated $52.7M.
  • PFM Health Sciences's ten largest holdings make up 37% of its $3.27B portfolio in Q1 2021.
  • PFM Health Sciences opened 28 new positions and closed 27 in Q1 2021.
  • PFM Health Sciences's portfolio value rose 15% quarter-over-quarter to $3.27B.

Based on PFM Health Sciences's 13F filing for Q1 2021, filed 17 May 2021.